Merus N.V. announced on April 23, 2025, the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting. The presentation will feature an updated analysis of interim clinical data from the Phase 2 trial of petosemtamab with pembrolizumab.
This data pertains to the first-line treatment of PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). The presentation will include data on the entire 45-patient dataset, building upon early clinical efficacy and safety data previously presented at 2024 ASCO®.
Merus plans to host a conference call on May 22, 2025, to discuss the full ASCO® data set. This upcoming presentation is a significant event for petosemtamab, as it will provide further insights into its efficacy and durability, reinforcing its potential as a new standard of care for r/m HNSCC.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.